Bolaños RH

Language: Spanish
References: 20
Page: 77-80
PDF size: 233.46 Kb.

ABSTRACT

Prehypertension is considered a precursor of stage 1 hypertension and a predictor of excessive cardiovascular risk. That’s why the Trial of Preventing Hypertension investigated whether pharmacologic treatment prevents or postpones stage 1 hypertension. Participants were randomly assigned to receive two years of candesartan or placebo, followed by two years of placebo for all. When a participant reached the study end point of stage 1 hypertension, treatment with antihypertensive agents was initiated. Both the candesartan group and the placebo group were instructed to make changes in lifestyle to reduce blood pressure throughout the trial. Over a period of four years, stage 1 hyperten-sion developed in nearly two thirds of patients with untreated prehypertension(the placebo group). Treatment of prehypertension with candesartan appeared to be well tolerated and reduced the risk of incident hypertension during the study period. Thus, treatment of prehypertension appears to be feasible.

REFERENCES

1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC7 report. JAMA 2003;289:2560-72. [Erratum, JAMA 2003; 290:197.]

2. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982;62: 347-504.

3. Greenlund KJ, Croft JB, Mensah GA. Prevalence of heart disease and stroke risk factors in persons with prehipertensión in the United States, 1999-2000. Arch Intern Med 2004;164:2113-8.

4. Julius S, Nesbitt S, Egan B, et al. Trial of preventing hypertension: design and 2-year progress report. Hypertension 2004; 44:146-51.

5. Julius S, Schork MA. Borderline hypertension— a critical review. J Chronic Dis 1971;23:723-54.

6. Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K. The association of borderline hypertension with target organ changes and higher coronary risk: Tecumseh Blood Pressure study. JAMA 1990; 264:354-8.

7. Leitschuh M, Cupples LA, Kannel W, Gagnon D, Chobanian A. High-normal blood pressure progression to hypertension in the Framingham Heart Study. Hypertension 1991;17:22-7.

8. Levy RL, Hillman CC, Stroud WD, White PD. Transient hypertension: its significance in terms of later development of sustained hypertension and cardiovascular-renal diseases. JAMA 1944;126:829-33.

9. Levy RL, White PD, Stroud WD, et al. Transient hypertension: the relative prognostic importance of various systolic and diastolic levels. JAMA 1945;128: 1059-61.

10. Liszka HA, Mainous AG III, King DE, Everett CJ, Egan BM. Prehypertension and cardiovascular morbidity. Ann Fam Med 2005;3:294-9.

11. Neaton JD, Kuller L, Stamler J, Wentworth DN. Impact of systolic and diastolic blood pressure on cardiovascular mortality. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis and management. 2nd ed. Vol. 1. New York: Raven Press, 1995:127-44.

12. Nesbitt SD, Julius S, Leonard D, Egan BM, Grozinski M. Is low-risk hypertension fact or fiction? Cardiovascular risk profile in the TROPHY study. Am J Hypertens 2005;18:980-5.

13. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endotheliumderived nitric oxide in the abnormal endothelium dependent vascular relaxa tion of patients with essential hypertension. Circulation 1993;87:1468-74.

14. Qureshi AI, Suri MFK, Kirmani JF, Divani AA, Mohammad Y. Is prehipertensión a risk factor for cardiovascular diseases? Stroke 2005;36:1859-63.

15. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, Md.: National Heart, Lung, and Blood Institute, 1997. (NIH publication no. 98-4080.)

16. Thomson KJ. Some observations on the development and course of hypertensive vascular disease. Proc Ann Meet Med Sect Am Life Conv 1950;38:85-112.

17. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001;358:1682-6.

18. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-7.

19. Hypertension Prevention Trial Research Group. The Hypertension Prevention Trial: three-year effects of dietary changes on blood pressure. Arch Intern Med 1990;150:153-62.

20. Vasan RS et al. Feasibility of Treating Prehypertension with an Angiotensin Receptor Blocker. New England Journal of Medicine 2006; 354: 1685-87.